What happened
On 16 November 2026, the US Food and Drug Administration began an agency-wide transition substituting the terms 'Super Intelligence' (SI) for 'Artificial Intelligence' (AI) across newly issued public-facing documents, digital communications, and web portals, implementing Executive Order 14434 of 29 September 2026 ('Inaugurating the Era of Super Intelligence'). The change is applied across CDRH, CDER and CBER digital health assets and public directories of cleared algorithmic software. The FDA clarified the shift is strictly terminological: it does not alter regulatory requirements, review standards, or submission pathways, does not require rebranding of marketed products, and preserves existing guidance such as Good Machine Learning Practice and Predetermined Change Control Plan frameworks. The statutory definition of AI under 15 U.S.C. 9401(3) is unchanged.
Why it matters
The action implements a cross-agency federal directive that renames AI as 'Super Intelligence' across official FDA communications and guidance hubs. It signals the federal government's standardised 'Super Intelligence' framing and could affect how sponsors, developers and academic investigators reference AI/ML in correspondence with the agency, even though it imposes no new evidentiary or substantive burden. It reflects ongoing federal AI policy realignment under EO 14434 and the parallel DOJ task force.
Action needed
Medical-device and digital-health sponsors should align public-facing and agency-facing references with the new 'Super Intelligence'/'SI' naming convention while preserving legacy guidance references; no change to regulatory filings, labelling or premarket submissions is required.